CagriSema in Clinical Trials: What Patients Should Know Cagrilintide 10mg Tirzepatide Australia Tirzepatide: a new low for bodyweight and blood glucose The Lancet Diabetes & Endocrinology In the REDEFINE 2 phase 3a trial involving adults with obesity and diabetes, the use of cagrilintidesemaglutide resulted in a significantly lower body weight than placebo at 68 weeks. Full trial results CagriSema misses noninferiority vs tirzepatide in REDEFINE 4; Novo Nordisk shares fall 15% iPharmaCenter CagriTirz (Cagrilintide + Tirz) >99% Purity